Breeze Holdings Acquisition Corp.
BREZW
NASDAQ Capital Market0.35
USD
-0.10
- -
CIK
0001817640
ISIN
US1067621151
CUSIP
106762115
Return %
Stock
S&P500
1Y
132.53
18.02
3Y
-52.22
64.11
5Y
-53.49
72.15
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- J. Douglas Ramsey Jr., Jr.
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 5324 Davis Boulevard North Richland Hills TX United States of America 76180
- CIK
- 0001817640
- Similar Companies
- Business
- Breeze Holdings Acquisition Corp. (BREZW) operates as a blank check company, or special purpose acquisition company (SPAC), whose primary business is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a focus on the defense technology industry; it offers no current products or services beyond its SPAC structure for capital raising and deployment into acquisition targets. Incorporated in 2020 and headquartered in Irving, Texas, the company functions as a subsidiary of Breeze Sponsor, LLC and trades warrants on Nasdaq under the BREZW ticker, targeting investors seeking exposure to private companies entering public markets through SPAC transactions. In a major strategic shift, Breeze completed a business combination with Taiwan-based YD Biopharma Limited in August 2025, following shareholder approval on August 14, 2025, and an initial merger agreement announced in September 2024 with subsequent amendments; the combined entity now operates as YD Bio Limited, trading ordinary shares and warrants on Nasdaq under the symbols YDES and YDESW, with an estimated enterprise value of nearly $700 million, shifting focus to biopharmaceuticals including innovative vaccines, therapeutic biologics for infectious diseases, cancer prevention diagnostics such as methylation detection for pancreatic cancer, exosome-based therapeutics, ophthalmology cellular drugs, and clinical testing supply for partners like Novartis. Prior to this merger, Breeze terminated a planned combination with TV Ammo, Inc. in August 2024 and began trading on OTCQX under BRZH, BRZHR, and BRZHW, while actively pursuing targets with a deadline extended to December 26, 2024. Geographically, the post-merger operations emphasize Taiwan-based development and manufacturing with global market aspirations via Nasdaq listing.